USFDA pulls up Intas Pharma for manufacturing lapses at Ahmedabad plant

US health regulator issues warning letter to Intas Pharmaceuticals CEO and MD Nimish Chudgar for manufacturing lapses and violation of CGMP regulations at the Matoda-Sanand facility in Ahmedabad. The USFDA found various manufacturing lapses and inadequate oversight in the company's Quality Assurance and production departments. Specifically, the investigation revealed manipulation of defect counts on visual inspection records to avoid rejection limits. The company also failed to thoroughly investigate discrepancies and establish written procedures for production controls and prevention of microbiological contamination.

from Business News: Latest News on Business, Stock Markets, Financial News, India Business & World Business News https://ift.tt/6jLQBWd
>

Comments

Popular posts from this blog

Katrina Kaif looks elegant as ever in a ruffled floral midi dress worth Rs. 15,000 for her visit to Sanjay Leela Bhansali's office

Salman Khan reveals the three villains of Radhe-Your Most Wanted Bhai; says they made the film look stronger and bigger

Dia Mirza admits Rehnaa Hai Terre Dil Mein had sexism in it